Curon Biopharmaceutical
PrivateLast Round
M&A
Oct 1, 2024
Est. Valuation
$214M
Total Funding Raised
$250M
Company Overview
Curon Biopharmaceutical is a biotechnology company that develops innovative cancer immunotherapies, including bispecific antibodies and antibody-drug conjugates.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Curon Biopharmaceutical Comparables
Compare Curon Biopharmaceutical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EpimAb Biotherapeutics | 79% | |
| Gilead Sciences | 78% | |
| Zenas BioPharma | 74% |
Curon Biopharmaceutical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Oct 1, 2024 | ||||
| Series B | Dec 28, 2019 | ||||
| Series A | Jul 27, 2018 |
Curon Biopharmaceutical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series B |
| Boyu Capital | Series A |
| Temasek | Series A |
| Oriza Holdings | Series B |
| Hillhouse Investment | Series B |
| Shengshan Asset Management | Series B |
| Lilly Asia Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2024
$700M round led by Merck & Co., Inc.
- Sep 28, 2024
Grew 67% QoQ, from 6 to 10 employees.
Curon Biopharmaceutical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Curon Biopharmaceutical's valuation, stock price, and market status.
Is Curon Biopharmaceutical a public or private company?
Curon Biopharmaceutical is a private company.
What is the current stock price of Curon Biopharmaceutical?
Curon Biopharmaceutical is a private company, so its shares have no public market price. Caplight tracks Curon Biopharmaceutical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Curon Biopharmaceutical worth (valuation)?
Curon Biopharmaceutical's valuation is estimated at $214.0M based on funding round data.
Can I buy Curon Biopharmaceutical stock?
Curon Biopharmaceutical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Curon Biopharmaceutical's last funding round?
Curon Biopharmaceutical's most recent funding round was M&A on October 1, 2024.
Who are the main investors in Curon Biopharmaceutical?
Key investors in Curon Biopharmaceutical include Temasek, Hyfinity Investments.
Will Curon Biopharmaceutical IPO soon?
No public IPO plans have been announced for Curon Biopharmaceutical.
How can I track Curon Biopharmaceutical secondary market activity?
Caplight tracks bids, offers, and trades in Curon Biopharmaceutical's shares on secondary markets.